Drugs / INDUSATUMAB VEDOTIN
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02391038 | Dec 2014 → Oct 2015 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01577758 | Jun 2012 → Feb 2014 | digestive system cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02202759 | Aug 2014 → Jan 2016 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02202785 | Jul 2014 → Jan 2016 | pancreatic adenocarcinoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INDUSATUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298045 ↗ |
| Known as | Indusatumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298045 ↗ |
| Known as | Indusatumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298045 ↗ |
| Known as | MLN0264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02202759 ↗ |
| Known as | TAK-264 | “A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.” PMID 28527133 ↗ May 2017 |
| Route | Intravenous | “intravenous (IV) infusion” NCT02202759 ↗ |
| Target | GUCY2C | “Heat-stable enterotoxin receptor binding agent” CHEMBL4298045 ↗ |